Tord is the Chairman of the Board of SciBase and has been a member of the board since 2014. Tord has extensive experience as a CEO in different MedTech companies and from Board assignments in both Swedish and international listed companies and owner-managed companies. Among other things, Tord has been the CEO of Synectics Medical Inc, Synectics Medical AB, Dantec AS, Artimplant AB, VP of Medtronic and Division Manager for Sandvik MedTech. Tord has an upper-secondary education in engineering and unfinished studies in industrial engineering from the Linköping University (1980-1984). In addition to his board work. Tord Lendau has been on multiple boards in the US, Holland, South Africa Korea etc and has amongst other also served as a Mentor and Speaker in Rapid Growth, Change and Talent Management for Executive Management Courses for the last 15 years.

Current assignments:
Chairman of the board of directors of Simpell Gig AB and Embedded Nano Europe AB. Board member of Seafire AB and Lendau Capital AB,.

Dr Leavitt joined the board in 2021. Dr. Leavitt, Executive Chairman, former CEO and Founder of Advanced Dermatology and Cosmetic Surgery (ADCS) is a board-certified Dermatologist and hair restoration/hair loss specialist. He is recognized both nationally and internationally as an accomplished physician, surgeon, educator, clinical researcher, lecturer, author and humanitarian. He is a member of a host of professional groups and societies including the American Academy of Dermatology, American Board of Hair Restoration Surgery (Founder), The American Osteopathic Association and the American Osteopathic College of Dermatology (Past President).

Current assignments:
Executive chairman of the board of directors of Advanced Dermatology and Cosmetic Surgery Group

Holdings in SciBase:
Holder of 239,000 shares.

Independence:
Dr Leavitt is independent in relation to the Company, the Company’s management and major shareholders.

Diana joined the Board in 2017. Diana holds an MBA from the University of Berlin and various follow-on educations among them an exam in medical marketing from UCLA (the University of California Los Angeles). Diana is today the CEO of Medskin Solutions Dr Suwelack AG with over 130 employees in Europe, the US and Japan. She has an extensive experience from various senior positions within the Pharmaceutical industry in both the US and Europe.

Current assignments:
CEO at Medskin Solutions Dr Suwelack AG.

Thomas joined the Board in 2017. Thomas is CFO of InflaRx NV (NASDAQ listed) and an independent advisor to companies in the healthcare industry. He has over 25 years of experience in senior management positions within the life sciences sector and as a venture investor. He has previously held positions as CFO of Medigene AG (publicly listed in Germany), as CEO and CFO of Epigenomics AG (publicly listed in Germany), where he led the company’s efforts in gaining regulatory approval for the company’s lead product with the FDA and oversaw its subsequent introduction into the US market, and as CFO at Biotie Therapies (Turku, Finland) and predecessor companies. Before that he was a venture investor for 7 years with Deutsche Venture Capital (DVC) and Burrill & Co. in the US. Thomas started his career at Hoechst AG (now Sanofi). Thomas holds a Ph.D. in organic chemistry from the Technical University of Berlin and has also studied economics, chemistry and physics at the University of Göttingen.

Current assignments:
CFO of InflaRx NV (NASDAQ listed), Chairman of the board Imcyse SA and member of the advisory committee at Advanced Market Discovery SL.

Independence
Thomas is independent in relation to the Company and the Company’s management and to the Company’s major shareholders.

Dr Dwarkasing is currently the Chief Scientific Officer at SkylineDx. She has over 10 years of life science experience with an international track record within oncology having held both research and management positions. Dr Dwarkasing has a strong academic background and a PhD in medical nutrition and pharmacology. Her drive for doing research is patient focus and how to bring science from bench to bedside. Her geographical areas of focus are the US, Europe and Australia.
Holdings in SciBase:
Holder of 0 shares.

Independence:
Dr Dwarkasing is independent in relation to the Company, the Company’s management and major shareholders.